📰 Eric Dobmeier News
Page 2 - Eric Dobmeier News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Eric Dobmeier. Real-time updates on events, politics, business and more.
June 13, 2023
Novartis is acquiring Chinook Therapeutics in a $3.2 billion deal that brings two late-stage drug candidates for a rare kidney disorder. The Novartis drug pipeline already has a molecule in late-stage development for the same kidney disease, which could raise questions from antitrust regulators.
June 12, 2023
Swiss drug giant will pay US$40 a share for Chinook; shareholders could receive an additional US$4 a share if further milestones are reached
June 12, 2023
Novartis agreed to buy Chinook Therapeutics for up to $3.5 billion.
June 12, 2023
Novartis announced June 12 that it will acquire Chinook Therapeutics, a Seattle-based biopharmaceutical company, for a total value of $3.5 billion.
June 12, 2023
Zigakibart treatment continues to demonstrate rapid and sustained reductions in mechanistic biomarkers, including IgA and Gd-IgA1 levels, which correspond...
June 7, 2023
06/07/23 Life Science Leader Newsletter
June 1, 2023
Advisory Research Inc. grew its stake in Chinook Therapeutics, Inc. (NASDAQ:KDNY – Get Rating) by 7.6% during the fourth quarter, Holdings Channel.com reports. The fund owned 31,101 shares of the company’s stock after acquiring an additional 2,207 shares during the period. Advisory Research Inc.’s holdings in Chinook Therapeutics were worth $815,000 at the end of […]
May 15, 2023
Chinook Therapeutics, Inc. (NASDAQ:KDNY – Get Rating) was the recipient of a significant growth in short interest in April. As of April 30th, there was short interest totalling 3,320,000 shares, a growth of 6.1% from the April 15th total of 3,130,000 shares. Approximately 8.0% of the company’s stock are short sold. Based on an average […]
May 11, 2023
Shares of Chinook Therapeutics, Inc. (NASDAQ:KDNY – Get Rating) have received an average rating of “Buy” from the nine research firms that are presently covering the company, Marketbeat.com reports. Seven analysts have rated the stock with a buy rating. The average 1 year price objective among brokerages that have issued ratings on the stock in […]
May 11, 2023
Chinook Therapeutics, Inc. (NASDAQ:KDNY – Get Rating) – Stock analysts at HC Wainwright upped their FY2027 earnings per share (EPS) estimates for shares of Chinook Therapeutics in a research report issued to clients and investors on Wednesday, May 10th. HC Wainwright analyst E. Arce now forecasts that the company will post earnings per share of […]